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Abstract. The burden of human immunodeficiency virus (HIV)-related disease in sub-Saharan Africa continues
to increase; providing adequate care for the huge number of people affected is a daunting task, especially given the
limited resources available. Recent studies have shown that low-cost regimens can prevent some of the most important
causes of HIV-related disease in African countries. Isoniazid preventive therapy can reduce the incidence of tuber-
culosis; priorities are to seek opportunities for implementation, to assess effectiveness under operational conditions,
and to monitor its effect on resistance patterns. Cotrimoxazole was shown to be highly effective in reducing morbidity
and mortality among individuals with symptomatic HIV disease in Coˆte d’Ivoire, and should be implemented where
it is likely to be of benefit. Pneumococcal polysaccharide vaccine was disappointingly ineffective among HIV-infected
Ugandan adults, but newer conjugate vaccines are becoming available that should be investigated. The benefit of
these preventive regimens to the individual may be modest when compared with the effect of antiretroviral therapy.
However, simple preventive therapies could reach a much wider population than is immediately feasible for expensive
and complex antiretroviral regimens, and thus have the potential for substantial benefit at the population level. The
availability of effective and affordable regimens to prevent HIV-related disease may also encourage people to seek
HIV testing, combat denial, and help overcome the sense of powerlessness in countries where the HIV epidemic has
hit hardest.
INTRODUCTION
The number of people estimated to be currently living
with human immunodeficiency virus (HIV) infection world-
wide continues to increase. The great majority of HIV-in-
fected people live in developing countries; of the 36.1 mil-
lion people estimated to be living with HIV/acquired im-
munodeficiency syndrome (AIDS) at the end of 2000, more
than 70% were in countries in sub-Saharan Africa.1
Providing care for HIV-infected people in low-income
countries is a daunting task. Most HIV-infected people living
in sub-Saharan Africa do not seek care until they have ad-
vanced disease2,3 and their mortality in hospital is high.2
However, many of the major HIV-related diseases in African
countries are both treatable and potentially preventable with
relatively inexpensive drugs. Several recently-published
studies from developing countries demonstrate that HIV-re-
lated disease can be prevented by such regimens.
Updating earlier work,4 we review published literature
concerning prevention of HIV-related opportunistic infec-
tions among adults in African countries. We summarize cur-
rent knowledge, suggest what preventive treatments should
be implemented, and what further research is needed.
OVERVIEW OF HIV-RELATED OPPORTUNISTIC INFECTIONS IN
AFRICAN COUNTRIES
Spectrum of disease. There are important geographic dif-
ferences in the spectrum of HIV-related disease.4,5 While
HIV-related disease in industrialized countries is well-de-
scribed, relatively few published studies describe the causes
of HIV-related disease in African countries. Facilities re-
quired to confirm the diagnosis of many HIV-related diseases
are not affordable in many of the countries with the greatest
burden of disease, and infrastructure for surveillance of HIV-
related disease is lacking. The information available comes
from a small number of published studies, most of which
are cross-sectional in design.
Table 1 shows the spectrum of HIV-related disease in four
African countries. Problems arise in comparing these studies
directly since the prevalence of specific conditions is affect-
ed by referral patterns, the study population (HIV clinic out-
patients in South Africa, hospitalized patients elsewhere), the
criteria for HIV testing (a systematic sample of all admis-
sions in Coˆte d’Ivoire and Kenya, only patients with sus-
pected HIV disease in Ethiopia), the diagnostic methods, and
the diseases reported (World Health Organization [WHO]
stage 3- and 4-defining conditions in Ethiopia, and only
WHO stage 4 conditions [Appendix 1] in South Africa). For
example, the apparent difference in the prevalence of bac-
teremia, a major cause of HIV-related hospital admission in
Coˆte d’Ivoire and Kenya but not reported from Ethiopia or
South Africa, may be primarily because blood cultures were
done routinely in the Coˆte d’Ivoire and Kenya studies. An-
other potential bias is that patients at the South African clinic
were routinely prescribed cotrimoxazole preventive therapy
if their CD4 count decreased below 200  106/L.
Tuberculosis (TB) is clearly the most important severe
HIV-related disease in African countries; TB and bacterial
diseases were the major causes of HIV-related disease in
Coˆte d’Ivoire, Ethiopia, and Kenya. South Africa has a more
‘‘western’’ spectrum of disease, although the spectrum varies
by ethnic group. In particular, TB was the most common
diagnosis among black and mixed race individuals, whereas
Pneumocystis carinii pneumonia (PCP) was most common
among white individuals.
Studies investigating the cause of bloodstream infections
among HIV-infected individuals admitted to hospital in Af-
rican countries are summarized in Table 2. Nontyphoid sal-
monellae are consistently the most common organisms iden-
tified; Streptococcus pneumoniae and Escherichia coli are
also common. The prevalence of Cryptococcus neoformans
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TABLE 1
Major causes of human immunodeficiency virus (HIV)-related disease in Coˆte d’Ivoire, South Africa, Kenya, and Ethiopia
Coˆte d’Ivoire5 South Africa6 Kenya7,8 Ethiopia3
Population HIV hospitalized
patients*
HIV clinic attenders, WHO
stage IV
HIV medical
admissions
Hospitalized patients
with suspected AIDS†
No. of HIV patients
Tuberculosis
Bacteremia
HIV wasting
Meningitis
349
28%
18%
11%
10%
Total
342
30%§
–
11%
–
White‡
12%§
13%
Black‡
51%§
5%
Mixed race‡
29%§
15%
95
18%
26%
–
–
79
51%§
–
34%
–
Isosporiasis
Bacterial pneumonia
Cerebral toxoplasmosis
Bacterial enteritis
Nonspecific diarrhea
7%
6%
6%
5%
5%
–
–
3%
–
–
1% 2% 4%
–
16%¶
–
–
15%
–
13%#
6%
–
–
Esophageal candidiasis
Cryptococcosis
Cytomegalovirus
Kaposi’s sarcoma
3%
2%
0
1%
17%
9%
9%
18%
18%
7%
13%
22%
13%
3%
2%
14%
20%
7%
0
14%
–
1%
–
2%
10%
–
–
–
Pneumocystis pneumonia
HIV encephalopathy
Chronic herpes simplex
0
0
0
22%
14%
13%
34%
23%
15%
8%
2%
10%
18%
11%
10%
–
–
–
1%
8%
3%
–  Data not available. Patients could have more than one diagnosis. Not all diagnoses are shown, so columns do not total 100%.
* Patients admitted to infectious diseases and respiratory wards.
† Patients admitted to referral hospital with clinical suspicion of acquired immunodeficiency syndrome (AIDS) or advanced HIV disease: World Health Organization (WHO) stage 3 and 4
conditions.
‡ Percentages estimated from graph.
§ Extrapulmonary.
¶ Acute cough and fever; 46% of this subgroup had pneumococci isolated from blood culture.
# Severe/recurrent bacterial infections.
in blood cultures varies widely between studies; this may be
partly due to differences in laboratory methods.
Cryptococcal disease is increasingly described as an im-
portant cause of HIV-related disease in African countries; it
was reported to be the third most common AIDS-defining
opportunistic infection in Rwanda,13 and cryptococcal men-
ingitis was the most common cause of meningitis among
hospitalized adults in Harare, Zimbabwe.14 Since effective
treatment is rarely affordable, cryptococcal disease may be
a more important cause of mortality than of morbidity; it
was the third most common cause of death in a cohort of
HIV-infected people in Uganda15 and the most common
cause of death among HIV-infected mineworkers in South
Africa (Corbett EL and others, unpublished data). Crypto-
coccal disease may be a lesser problem in West Africa, al-
though there are few comparable studies; in Coˆte d’Ivoire,
it was the cause of death in only 3% of HIV-infected pa-
tients.16
Level of immunosuppression at which severe disease
occurs. Since CD4 counts are rarely available in African
countries, there is little information about the level of im-
munosuppression at which HIV-related disease occurs. Ex-
isting data, however, suggest that most HIV-infected individ-
uals admitted to hospital have severe immunosuppression.
The median CD4 count among HIV-infected patients admit-
ted to the infectious diseases and respiratory medicine wards
in Abidjan, Coˆte d’Ivoire was 87 and 167  106/L, respec-
tively,2,9 compared with 83  106/L in Addis Ababa, Ethi-
opia.3
Improving the outcome for HIV-infected individuals with
advanced disease under these circumstances is likely to be
difficult. It would require patients to seek care earlier in their
illness, diagnostic facilities to be accessible, and treatment
to be affordable; although many of these diseases can be
treated, the cost (of, for example, antifungal therapy) is cur-
rently prohibitive, particularly since long-term secondary
prophylaxis is often required.
Conclusions. Many important causes of HIV-related dis-
ease in African countries are preventable. Although major
improvements in survival are unlikely without combination
antiretroviral therapy,17 relatively simple and inexpensive
preventive therapy is an attractive option for HIV-infected
people. HIV-infected individuals would need to be identified
earlier in the course of disease for such preventive therapy
to be effective; wider uptake of voluntary counseling and
testing could achieve this.
The major potential targets for prevention in African
countries are TB, bacterial infections including pneumococ-
cal disease and nontyphoid salmonella, toxoplasmosis, and,
in some areas, cryptococcal disease. Studies that have eval-
uated preventive regimens relevant to HIV-infected people
in African countries are discussed in the following sections.
PREVENTING TUBERCULOSIS
What we know. A number of trials have evaluated the
efficacy of primary preventive therapy against TB among
HIV-infected individuals (Table 3). In all the trials, preven-
tive therapy reduced the incidence of TB among HIV-in-
fected people with a positive tuberculin skin test. However,
the results were not always statistically significant; in some
trials this was probably because of low statistical power due
to a small number of participants with positive tuberculin
tests. In the two meta-analyses, the effect in people with
positive tuberculin tests was both statistically and clinically
significant, with a reduction in the risk of TB by 60% and
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TABLE 2
Cause of bacteremia among human immunodeficiency virus (HIV)-infected patients admitted to hospitals in five African countries
Country
Population
No. HIV-infected patients
Coˆte d’Ivoire2,9
Acute medical
admissions‡
349
Tanzania10
Febrile medical
admissions
282
Uganda11
Febrile medical
admissions
227
Coˆte d’Ivoire12
Infectious diseases
admissions
202
Rwanda†
Febrile medical
admissions
163
Kenya7
Acute medical
admissions
95
No. (%) with blood stream infections, excluding mycobacteria§
63 (18%) 118 (42%) 61 (27%) 39 (19%) 52 (32%) 26 (27%)
Organisms identified (% of total with blood stream infection)
Nontyphoid salmonella
Streptococcus pneumoniae
Escherichia coli
Cryptococcus neoformans
Other
No. (%) with mycobacteremia
56%
17%
17%
0%
11%
–
23 (36%)
6 (9%)
7 (11%)
10 (16%)
18 (28%)
57 (20%)
13 (41%)
11 (34%)
2 (6%)
0
6 (19%)
30 (13%)
16 (41%)
3 (8%)
4 (10%)
5 (13%)
12 (31%)
10 (5%)
10 (19%)
12 (23%)
–
13 (25%)
17 (33%)
1 (0.5%)
10 (38%)
7 (27%)
2 (8%)
1 (4%)
6 (23%)
–
–  data not available.
† Taelman and others, unpublished data.
‡ Infectious diseases and respiratory wards combined; a weighted average was used to allow for unequal sampling; therefore, absolute numbers are not given.
§ Clinically important organisms. Since cultures for mycobacteria were not done in all studies, to facilitate comparison, mycobacterial isolates have been excluded from this analysis, but
fungi are included. Some individuals had more than one organism; thus, totals may exceed 100%.
TABLE 3
Summary of randomized, placebo-controlled trials and meta-analyses of tuberculosis preventive therapy in human immunodeficiency virus–
infected people
Study Researcher Country Regimen*
Unadjusted relative risk of tuberculosis
Point estimate (95% confidence interval)
PPD PPD Anergic All
Randomized controlled trials
1
2
3
Pape18
Valdespino‡
Wadhawan§
Haiti
Mexico
Zambia
12H
6H
6H
0.17
(0.03-0.83)
0.19
(0–13.72)
–
0.56
(0.11–2.5)
–
–
–
–
–
0.29
(0.09–0.9)
–
0.4
(0.2–0.82)
4
5
Hawken19
Whalen20
Kenya
Uganda
6H
6H
3RH
0.70¶
(0.29–1.78)
0.33
(0.14–0.77)
0.40
(0.18–0.86)
1.20·
(0.52–2.46)
–
–
–
0.83
(0.34–2.04)
–
1.11
(0.64–1.98)
–
–
6
7
Gordin21
Mwinga22
United States
Zambia
3RHZ
6H
6H2
0.51
(0.24–1.08)
–
0.25¶
(0.05–1.14)
–
–
0.86¶
(0.31–2.38)
–
0.48
(0.12–1.91)
–
–
–
0.62
(0.38–0.99)
3RZ2
Combined
0.3¶
(0.06–1.4)
0.27
(0.08–0.87)
1.25¶
(0.49–3.16)
1.06
(0.46–2.46)
0.58
(0.35–0.95)
Meta-analyses Studies included
Wilkinson23 1,4,5,6 0.32
(0.19–0.51)
0.82
(0.50–1.36)
– 0.57
(0.41–0.79)
Bucher24 1–7 (isoniazid arms only) 0.40
(0.24–0.65)
0.84
(0.54–1.30)
– 0.58
(0.43–0.8)
* Drug regimens: H  isoniazid; R  rifampicin; Z  pyrazinamide. The prefix indicates the duration of the regimen in months; the subscript indicates the number of doses per week if
the regimen was intermittent rather than daily. PPD  positive tuberculin skin test; PPD  negative tuberculin skin test.
‡ Data from Bucher and others.24
§ Wadhawan D and others, unpublished data.
¶ Data from Hawken and Muhindi.25
68%, respectively. Among individuals who had either a neg-
ative tuberculin test or were anergic, TB preventive therapy
had no significant protective effect in any of the studies or
meta-analyses. Most of the trials that evaluated the effect of
preventive therapy irrespective of tuberculin test result found
that preventive therapy protected against TB (Table 3). In
support of these findings, the meta-analyses both produced
statistically significant results among all individuals regard-
less of tuberculin status, with pooled estimates of reduction
in TB incidence of 43%23 and 42%.24
Only one trial18 showed a significant reduction in mortality
rates in the intervention group. Most studies were not de-
signed to examine this question and had inadequate statis-
tical power to detect a significant effect on mortality rates.
In the meta-analyses, the study of Wilkinson and others
found a pooled estimate for a reduced risk of death of 27%
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(95% confidence interval [CI]  5–43%) among the sub-
group with a positive tuberculin test, but no significant effect
on mortality rates for the entire group,23 while the study of
Bucher and others found no effect on mortality rates, either
overall or in the tuberculin-positive subgroup.24
What we don’t know. Who should receive TB preventive
therapy? Preventive therapy is only of proven benefit to
HIV-infected people with a positive result on a tuberculin
skin test, and so preventive therapy should ideally be re-
stricted to this group. However, performing tuberculin tests
in low-income countries is not easy; staff need special train-
ing, tuberculin is not always available, individuals must re-
turn to have their tests read at 48 hr, and nosocomial trans-
mission of HIV and other pathogens may occur. In popula-
tions where the prevalence of tuberculous infection or the
risk of new infection is high, preventive therapy is likely to
be beneficial and should be implemented even if tuberculin
tests cannot be carried out. WHO and the Joint United Na-
tions Programme on HIV/AIDS (UNAIDS) recommend that
if tuberculin skin testing is not feasible, HIV-infected indi-
viduals may be considered for preventive therapy if the prev-
alence of tuberculous infection in the population is more
than 30%, or if they are health care workers, household con-
tacts of TB patients, prisoners, miners, or members of other
groups at high risk of acquiring TB.26
How long should preventive therapy be given? In the pre-
HIV era, studies in immunocompetent individuals suggested
that the optimum duration of isoniazid preventive therapy
for maximum reduction of TB incidence was 12 months.27
However, on the basis of cost-effectiveness and the risk of
hepatitis, six months of isoniazid was considered prefera-
ble.28 The Centers for Disease Control and Prevention and
American Thoracic Society guidelines now recommend nine
months of isoniazid for both HIV-infected and uninfected
individuals.29 In the early studies, the rationale for preventive
therapy was to eradicate latent tuberculous infection.27 How-
ever with the advent of the HIV pandemic, the importance
of recent infection as well as reactivation of latent infection
in HIV-infected people is now appreciated.30 In recent stud-
ies among South African gold miners, most TB was attri-
buted to ongoing transmission,31 and reinfection was more
frequent than relapse as a cause of recurrent TB among HIV-
infected gold miners (Sonnenburg P and others, unpublished
data). Where newly acquired infection is an important con-
tributor to active TB, a longer or even indefinite course of
preventive therapy may be more effective.
Studies of TB preventive therapy among HIV-infected in-
dividuals support the idea that six months may be too short.
In two of these studies, the efficacy of preventive therapy
decreased with time after preventive treatment was stopped22
(Wadhawan D and others, unpublished data) such that one
year after completing preventive therapy, the incidence of
TB in the treated groups was similar to that in the placebo
group.22 In Haiti, where twice a week isoniazid for six
months was compared with twice a week rifampicin plus
pyrazinamide for three months, the risk of TB was signifi-
cantly lower in the group receiving six months of isoniazid
during the first 10 months of the trial.32 Among all placebo-
controlled trials of preventive therapy, the maximum protec-
tive effect found was in the trial evaluating 12 months of
isoniazid;18 all the other trials evaluated shorter regimens.
In summary, TB preventive therapy may be more effec-
tive if given for longer than six months, or even indefinitely,
but evidence of superiority over a six-month regimen is lack-
ing. Longer or indefinite preventive therapy regimens might
be associated with reduced adherence, and this would need
to be monitored.
What is the effect of preventive therapy on antituberculous
drug resistance? There are concerns that the widespread in-
troduction of preventive therapy may increase the prevalence
of drug-resistance among isolates of Mycobacterium tuber-
culosis, although this is not supported by evidence from tri-
als conducted in the pre-HIV era.33 Theoretically, the use of
isoniazid as a single agent in preventive therapy in individ-
uals with latent infection with an isoniazid-resistant organ-
ism would be ineffective but would not promote drug resis-
tance. However, isoniazid monotherapy given to individuals
with undetected active TB might result in acquired resistance
to isoniazid. This is of particular concern among HIV-in-
fected people in whom active TB may be prevalent34 and
difficult to diagnose. It is therefore important to identify in-
dividuals with active TB and ensure that they receive full
antituberculous treatment.
An alternative approach would be to use preventive ther-
apy regimens with more than one drug, which would resolve
the problem of persons with active disease unintentionally
receiving isoniazid monotherapy. However, multidrug pre-
ventive therapy regimens are expensive, and if unsupervised
preventive therapy regimens including rifampicin were in-
troduced, resistance to this key antituberculous agent might
be promoted. It will be important to monitor the effect of
preventive therapy on antituberculous drug resistance.
Another question concerns what regimen is appropriate in
populations where there is already a high prevalence of re-
sistance to isoniazid and other antituberculous drugs. Few
data from African countries document the prevalence of an-
tituberculous drug resistance, but evidence suggests that
there is already significant primary resistance in several
countries. For example, primary resistance to at least isoni-
azid and rifampicin was reported among 5.3% patients in
Coˆte d’Ivoire during the period 1995–1996.35 Where the
prevalence of primary isoniazid resistance is high, preven-
tive therapy with more than one agent may be considered,
but this must be balanced against the risks of promoting
rifampicin resistance if unsupervised rifampicin-containing
regimens are used.
What is the best way to exclude active tuberculosis? It is
important to ensure that individuals with active TB do not
receive isoniazid monotherapy. The best way to screen peo-
ple to detect those with active disease is not clear; studies
are needed to determine whether a symptom screen is ade-
quate or whether radiologic and microbiologic investigations
are required. The need for a screening system with adequate
sensitivity to detect active disease needs to be balanced
against the expense of the investigations required. In addi-
tion, a complex screening system requiring multiple visits
may deter people from starting preventive therapy (Ayles H
and others, unpublished data).
Impact and cost-effectiveness of tuberculosis preventive
therapy. Since TB preventive therapy has not yet been wide-
ly introduced, there are no data on its effectiveness and im-
pact on TB control; these will need to be evaluated. Mod-
814 GRANT AND OTHERS
TABLE 4
Comparison of two studies of the efficacy of cotrimoxazole among symptomatic human immunodeficiency virus-infected people in Abidjan,
Coˆte d’Ivoire*
Study
Population
Anglaret and others45
Health center
attenders,
WHO stage 2/3
Wiktor and others44
Newly diagnosed TB
patients (i.e., at least
WHO stage 3)
Population characteristics
Number of participants
Total follow-up time (person years)
Follow up duration† (months)
Baseline CD4 level† ( 106/L)
Cotrimoxazole
271
190
9.6
322
Placebo
270
157
9.5
331
Cotrimoxazole
386
366
10.8
311
Placebo
385
333
10.1
325
Main outcome measures
No. of hospitalizations
Hospitalization rate (per 100 person years)
Rate ratio for hospitalization
79
41.6
(not given)
162
103.2‡
29
8.2
0.57 (0.36–0.90)
47
15.0
Deaths
Death rate (per 100 person years)
Mortality hazard ratio
Severe event hazard ratio
41
21.2
0.87 (0.57–1.32)
0.57 (0.43–0.75)
46
29.3
51
13.8
0.54 (0.38–0.77)
86
25.4
* WHO  World Health Organization; TB  tuberculosis.
† Mean in the study of Anglaret and others; median in the study of Wiktor and others.
‡ Crude estimate based on published data, not allowing for multiple events.
eling exercises suggest that TB preventive therapy is likely
to be cost-effective.36,37 However, all such models are highly
dependent on their baseline assumptions, and it will be im-
portant to confirm these estimates with real data.
Is secondary preventive therapy effective? Little work has
been done to evaluate secondary preventive therapy for HIV-
infected individuals who have previously been treated for an
episode of TB. In a double-blind trial in Zaire, HIV-infected
patients completing short course chemotherapy for TB were
randomly assigned to receive an additional six months of
twice a week rifampicin plus isoniazid or placebo. The in-
tervention group had a significantly lower rate of TB recur-
rence (1.9% versus 9%; P  0.01) although losses to follow-
up were high.38 In an open trial among HIV-infected adults
who had completed treatment for pulmonary TB in Abidjan,
Coˆte d’Ivoire, the incidence of TB in the isoniazid plus sul-
phadoxine-pyrimethamine group versus the untreated group
was 2.1 versus 7.0 per 100 person years (relative risk [RR]
 0.3, 95% CI  0.09–0.94).39 In a study in Haiti, individ-
uals completing short course TB treatment were randomly
assigned to receive 12 months of isoniazid as post-treatment
prophylaxis or placebo.40 Among HIV-infected participants,
the incidence of TB was lower in the group receiving iso-
niazid compared with controls (1.4 versus 7.8 per 100 person
years, RR  0.18, 95% CI  0.04–0.83); it was noted that
recurrent TB occurred only in individuals who had symp-
tomatic HIV disease before their initial diagnosis of TB. It
seems likely that secondary preventive therapy against TB
would be beneficial in areas where the risk of TB infection
is high. Further clarification of who would benefit and the
optimum duration of therapy (fixed or lifelong) would be
valuable, particularly in view of the large number of poten-
tially eligible HIV-infected individuals. Secondary TB pre-
ventive therapy is less likely to be useful in regions where
TB prevalence is lower and the risk of reinfection is corre-
spondingly smaller.
Conclusions. Implementation of TB preventive therapy.
TB preventive therapy is effective against the most impor-
tant HIV-related disease in sub-Saharan Africa, and should
be implemented where feasible. The top priority for National
TB Control Programs remains the detection and treatment of
active cases of TB, and the implementation of preventive
therapy should not be at the expense of this goal. However,
case detection and treatment is proving inadequate to control
TB in countries with high HIV prevalence.41 Preventive ther-
apy may be an important part of a broader program neces-
sary to interrupt TB transmission in countries severely af-
fected by the HIV epidemic, but it would probably have to
be used very widely to achieve a significant public health
benefit.
A major barrier to implementing preventive therapy is the
identification of asymptomatic HIV-infected individuals who
would benefit from this treatment. As a first step, opportu-
nities to implement preventive therapy need to be sought
within health structures where HIV counseling and testing
is already being provided. This intervention could have wid-
er benefits, since the availability of effective treatment may
provide an incentive for people to attend for voluntary coun-
seling and testing for HIV (Godfrey-Faussett P and others,
unpublished data). Existing services providing care for HIV-
infected individuals are in an ideal position to implement TB
preventive therapy. Other services that routinely provide vol-
untary counseling and testing, such as antenatal services,
might be able to initiate TB preventive therapy. Further op-
portunities could be created in occupational health settings,
since TB prevention could be cost-beneficial to employers.
Assurance of confidentiality would be crucial.
Research priorities. Research priorities to enable the suc-
cessful translation of TB preventive therapy to operational
practice include studies determining how best to detect ac-
tive TB among individuals potentially eligible for preventive
therapy. Studies are needed to determine the optimum du-
ration of TB preventive therapy, comparing the current stan-
dard of six- or nine-month regimens with indefinite preven-
tive therapy; two such studies are due to start in South Africa
and Botswana. Studies to evaluate effectiveness under op-
erational conditions are required; these will also need to
measure adherence to treatment. Resistance to antitubercu-
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lous drugs should be monitored. Other important areas in-
clude ways to promote and sustain adherence to preventive
therapy.
PREVENTING OPPORTUNISTIC INFECTIONS WITH COTRIMOXAZOLE
What we know. In industrialized countries, the earliest
improvements in survival with HIV infection were due to
improved treatment for common opportunistic infections and
the introduction of cotrimoxazole as preventive therapy
against PCP.42 Since PCP is far less common among adults
in most African countries than in the United States and Eu-
rope,43 it was uncertain whether cotrimoxazole would be a
useful intervention for African populations. However, some
of the major causes of illness and death such as bacterial
infections (particularly nontyphoid salmonellosis and pneu-
mococcal disease) and cerebral toxoplasmosis are potentially
preventable using cotrimoxazole, which is inexpensive and
widely available in many low-income countries. Trials were
therefore set up to evaluate the safety and efficacy of cotri-
moxazole among HIV-infected people in African countries.
Efficacy of cotrimoxazole among HIV-infected populations
in African countries. Two large placebo-controlled studies
have examined the efficacy of cotrimoxazole (960 mg a day)
in African populations, both conducted in Abidjan, Coˆte
d’Ivoire. Wiktor and others recruited HIV-infected individ-
uals with newly diagnosed pulmonary TB (at least WHO
stage 3) from TB clinics.44 The main outcome measures were
hospitalization or death from any cause. In a simultaneous
study by Anglaret and others, HIV-infected individuals in
WHO stage 2 or 3 (i.e., symptomatic disease, including pul-
monary TB, but excluding those with major opportunistic
infections) were recruited from community clinics.45 The
main outcome measure was the ‘‘severe event’’ rate; i.e.,
death or hospitalization from any cause.
The main results of these studies are compared in Table
4. In the study of Wiktor and others,44 both the hospitaliza-
tion rate and the mortality rate were significantly reduced in
the cotrimoxazole group (rate ratio for hospitalization 
0.57, 95% CI  0.36–0.90; hazard ratio for mortality  0.54,
95% CI  0.38–0.77). The effect on mortality rate was only
seen in those with baseline CD4 counts less than 350  106/
L. In the study of Anglaret and others,45 severe events were
significantly reduced in the cotrimoxazole group (hazard ra-
tio  0.57, 95% CI  0.43–0.75). Most of the severe events
were hospitalizations, and there was no significant difference
in the mortality rate (hazard ratio  0.87, 95% CI  0.57–
1.32). There was a significant difference in the event rates
between cotrimoxazole and placebo groups in all three strata
of baseline CD4 count (number of persons with severe
events: CD4  500 106/L: 6 versus 21, hazard ratio  0.27
[95% CI  0.11–0.68]; CD4 200–499  106/L: 31 versus
39, hazard ratio  0.55 [95% CI  0.34–0.88]; CD4  200
106/L: 47 versus 64, hazard ratio  0.66 [95% CI  0.45–
0.97]).
The two studies were similar in showing a significant re-
duction in morbidity in the cotrimoxazole group. However
they differed in that only the study of Wiktor and others
found a significantly reduced mortality rate in the group re-
ceiving cotrimoxazole. Furthermore, the study of Anglaret
and others found cotrimoxazole to have a beneficial effect
at all levels of baseline CD4 count, whereas the study of
Wiktor and others found benefit only in subgroups with a
CD4 count less than 350  106/L at study entry.
How can these differences be explained? Patients in the
study of Wiktor and others might have had more advanced
disease (all had pulmonary TB, at least WHO stage 3) than
those in the study of Anglaret and others (WHO stage 2 or
3). However, because the baseline CD4 count was almost
identical in the two study populations, and the mortality rates
were similar in the control groups of the two studies, this
seems unlikely. The higher hospitalization rate in the study
of Anglaret and others was probably due to inclusion of less
severe events than in the study of Wiktor and others. In the
study of Anglaret and others, hospitalizations included ad-
missions to a dedicated study day-care center, whereas in the
study of Wiktor and others, patients requiring hospitalization
were referred to one of the university hospitals. This is sup-
ported by the causes of morbidity identified. In the study of
Anglaret and others, the most frequent severe events were
nonspecific enteritis, herpes zoster, and acute unexplained
fever; these events would not necessarily have led to hos-
pitalization in the study of Wiktor and others. If the study
of Anglaret and others ‘‘captured’’ more minor illness, such
as malaria, this may explain why cotrimoxazole was found
to reduce morbidity at all CD4 counts in this study but not
in the study of Wiktor and others.
The absence of a significant effect on mortality rates in
the study of Anglaret and others could have been due to lack
of statistical power, since this study was not designed to
detect a difference in mortality rates. Given the observed
mortality rates, the study had only about 32% power to de-
tect a statistically significant difference at the 5% level.
An important finding of both studies was that cotrimox-
azole was well tolerated with very few serious adverse
events. In the study of Anglaret and others, three adverse
events were deemed ‘‘probably’’ due to cotrimoxazole, only
two of which led to discontinuation of the drug (because of
rash). There was a significant excess of neutropenia (mostly
mild or moderate) in the cotrimoxazole group. In the study
of Wiktor and others, adverse events were more frequent in
the placebo than the cotrimoxazole group, and permanent
discontinuation of study medication was required in 2.7% of
the patients in both the cotrimoxazole and placebo groups.
This supports previous observational data reporting a low
incidence of cutaneous reactions to cotrimoxazole in HIV-
infected African individuals.46
Two other studies support the usefulness of cotrimoxazole
or similar therapy among HIV-infected individuals. In an
open randomized controlled trial, daily isoniazid plus weekly
sulfadoxine-pyrimethamine was compared with no treatment
among 263 HIV-infected patients who had completed treat-
ment for pulmonary TB in Abidjan.39 Symptoms were less
frequent in the intervention group (rate ratio  0.35, 95%
CI  0.31–0.4) as were ‘‘sick days’’ (rate ratio  0.21, 95%
CI  0.13–0.34), although the reduction in mortality rates
was not statistically significant (rate ratio  0.64, 95% CI
 0.35–1.17). Part of the reduction in morbidity was due to
a reduction in TB incidence, but the number of TB events
was relatively small (4 versus 10), suggesting that sulfadox-
ine-pyrimethamine probably contributed to the reduction in
morbidity. Further support comes from an observational
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study from Cape Town, South Africa, in which 71 HIV-
infected patients with TB and CD4 counts  200  106/L
who received cotrimoxazole (480 mg a day) were compared
with historical controls.47 The incidence of cotrimoxazole-
preventable disease (PCP, cerebral toxoplasmosis, nonty-
phoid salmonellosis, bacterial pneumonia) was significantly
lower in the cotrimoxazole group (rate ratio  0.23, 95% CI
 0.06–0.84), and mortality rates were also significantly re-
duced.
Other trials of cotrimoxazole as prophylaxis against HIV-
related disease were started in Senegal (Maynart M and oth-
ers, unpublished data), Malawi, and South Africa, but re-
cruitment to the placebo-controlled phase was stopped (when
the results of the Abidjan studies were released) before de-
finitive results were reached. In Malawi and South Africa,
the intervention groups are being compared with historical
controls (Zijlstra EE and others, unpublished data; Church-
yard G and others, unpublished data), and operational eval-
uations are in progress in Malawi (Zachariah R and others,
unpublished data) and South Africa (Grant AD and others,
unpublished data; Hausler H and others, unpublished data).
In conclusion, the Abidjan studies provide convincing ev-
idence that cotrimoxazole preventive therapy is well-toler-
ated and results in clinically important reductions in mor-
bidity and mortality rates among West African people with
symptomatic HIV disease. The report from Cape Town sug-
gests that it may also be of benefit in other African popu-
lations.
What we don’t know. The most important question is
whether the results of the randomized controlled trials from
Abidjan can be generalized to other regions in sub-Saharan
Africa. The results may not be applicable elsewhere because
of regional differences in, first, the spectrum of HIV-related
disease, and, second, the prevalence of resistance of relevant
pathogens to cotrimoxazole.
Differences in spectrum of HIV-related disease. To predict
whether cotrimoxazole will be effective in other parts of
Africa, we need to consider what diseases were prevented
in the published studies. In the study of Wiktor and others,
cotrimoxazole resulted in a statistically significant reduction
in the incidence of hospitalization attributed to enteritis due
to isosporiasis and nontyphoid salmonella, and to nonty-
phoid salmonella septicemia. The incidence of hospitaliza-
tion due to bacterial chest infections, anemia, urinary tract
infections, and cerebral toxoplasmosis was lower in the
group receiving cotrimoxazole, but the number of events in
each category was small and the difference was not statis-
tically significant. In the study of Anglaret and others, there
was a significant reduction in hospitalization due to bacterial
pneumonia, malaria, isosporiasis, and acute unexplained fe-
ver. Thus, cotrimoxazole may be expected to be effective in
regions where these diseases are major causes of HIV-related
morbidity and mortality.
The spectrum of disease as reported from Kenya is broad-
ly similar to that in Coˆte d’Ivoire. There are very few com-
parable data available from southern Africa, but in South
Africa there may be proportionally less diarrheal disease,
salmonellosis, and toxoplasmosis (Corbett E and others, un-
published data). It is therefore uncertain whether cotrimox-
azole will be beneficial in this region, although the study
from Cape Town suggests that it may be.
Resistance to cotrimoxazole. Another issue determining
the effectiveness of cotrimoxazole as preventive therapy is
the prevalence of cotrimoxazole resistance among relevant
bacterial pathogens, in particular nontyphoid salmonellae
and pneumococci. The prevalence of cotrimoxazole resis-
tance among enterobacteriacae in Abidjan is relatively low;
in an earlier study, the prevalence of cotrimoxazole resis-
tance among nontyphoid salmonellae in 1995 was 14%.48
This compares with 46% in Kenya in 1993–199449 and 83%
in Malawi in 1998,50 and 39%51 and 90%52 among Salmo-
nella spp. in Ethiopia during 1995 and in 1994–1996, re-
spectively.
Among isolates of Streptococcus pneumoniae, there is
also considerable regional variation in antibiotic resistance
patterns. Comparisons are complicated by differences in the
prevalence of resistance between adults and children, be-
tween invasive and noninvasive isolates, and by differences
in the method used to determine resistance. The reported
prevalence of resistance to cotrimoxazole varies widely, re-
ported at 54% among invasive organisms in Kenyan adults,53
91% in Malawi in 1998 (population not specified),50 and
10% among invasive organisms in South African adults.54
Published data from Coˆte d’Ivoire are sparse; during 1994–
1996, 73% of 11 invasive S. pneumoniae isolates from adult
inpatients were resistant to cotrimoxazole.48
These data suggest that cotrimoxazole may be less effec-
tive in preventing nontyphoid salmonellae in African coun-
tries outside Coˆte d’Ivoire, particularly in southern and east-
ern Africa, and the effect on pneumococcal disease is un-
certain. However, no data confirm whether in vitro resistance
correlates with lack of effectiveness in vivo, and the data
from South Africa mentioned earlier provide some cause for
optimism.
Who should receive cotrimoxazole? The two large trials
of cotrimoxazole leave some uncertainty about who should
receive cotrimoxazole. Patients with TB may benefit more
from cotrimoxazole than other HIV-infected individuals, be-
cause while they are being treated, they are no longer at risk
for TB, thus removing a major cause of morbidity and mor-
tality that is not amenable to prevention with cotrimoxazole.
Among individuals in WHO stage 2 and 3, cotrimoxazole
reduced morbidity, perhaps due to conditions that were less
severe but probably important in terms of quality of life and
working capacity. Since neither study evaluated individuals
in WHO stage 4, there is no specific evidence that cotri-
moxazole is beneficial in this group, although this seems
highly likely, because in the study of Wiktor and others the
protective effect of cotrimoxazole increased with decreasing
CD4 count.
Conclusions. Implementation of cotrimoxazole preventive
therapy. Since cotrimoxazole reduced morbidity and mor-
tality in the studies from Abidjan, it should be implemented
among individuals with symptomatic HIV disease, particu-
larly those with TB, in situations where the spectrum of HIV-
related disease and resistance patterns suggest that it is likely
to be effective. This could be implemented through TB con-
trol programs and existing HIV clinics. As with TB preven-
tive therapy, a first step would be to seek other opportunities
to implement cotrimoxazole preventive therapy within health
care systems where HIV counseling and testing is already
available.
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Asymptomatic individuals (i.e., WHO stage 1) were not
included in any of these studies; therefore, there is no evi-
dence to guide a decision concerning when cotrimoxazole
should be started in African countries. It would also be use-
ful to be able to ‘‘target’’ preventive therapy to those most
likely to benefit. One approach might be use trial data to
derive ‘‘numbers needed to treat’’ to prevent specified out-
comes at different baseline CD4 counts. For example, using
mortality rates from the study of Wiktor and others, the num-
ber of people needed to receive treatment with cotrimoxa-
zole for one year to prevent one death would be 1.5, 7, 6,
and 77 for CD4 counts 0–99, 100–199, 200–349, and  350
 106/L, respectively. Clearly, in the majority of resource-
poor settings CD4 counts are not available; thus, a surrogate
such as total lymphocyte count would need to be used.
In regions where the effectiveness of cotrimoxazole is un-
certain because of a high prevalence of cotrimoxazole resis-
tance or differences in the spectrum of HIV-related disease,
the situation is less clear. Since cotrimoxazole is safe and
inexpensive, it would be appropriate to implement in situa-
tions where it is likely to be of benefit. It will be important
to find ways of assessing and monitoring its effectiveness;
this could be done by means of incremental introduction,
historical comparisons, or case-control studies. Where it is
uncertain whether cotrimoxazole will have significant ben-
eficial effects, further trials may be appropriate.
Research priorities. The effectiveness of cotrimoxazole
under operational conditions is unknown and will need to be
evaluated. As with TB preventive therapy, adherence is like-
ly to be a key determinant of effectiveness, and practical
ways of promoting and monitoring adherence need to be
found. The effect of long-term low-dose cotrimoxazole on
antibiotic resistance patterns should be monitored. Wide-
spread use of cotrimoxazole preventive therapy is likely to
result in an increase in cotrimoxazole resistance,55 which will
require monitoring, and ultimately alternative agents may
need to be identified.
PREVENTING PNEUMOCOCCAL DISEASE
What we know. Pneumococcal polysaccharide vaccine
(PPV) was first evaluated among military personnel in the
1940s56 and mineworkers in South Africa in the 1970s,57 and
was found to be highly effective in preventing pneumococcal
pneumonia in these immunocompetent populations. As the
prevalence of antibiotic resistance among pneumococci in-
creases,58 vaccination becomes a more attractive intervention
since it does not depend on adherence to medication and
does not promote antibiotic resistance. Pneumococcal dis-
ease is an important cause of HIV-related morbidity and
mortality in African populations.59 The Centers for Disease
Control and Prevention ‘‘generally recommend’’ PPV for
HIV-infected persons,60 although the evidence of efficacy in
this group comes from observational studies in the United
States,61–63 not randomized controlled trials. Interestingly,
one of these studies found reduced vaccine effectiveness in
African Americans for reasons that were not clear.63
With this background, the results of a randomized con-
trolled trial of PPV among HIV-infected Ugandan adults are
of particular interest. 23-valent PPV was compared with pla-
cebo among 1,392 HIV-infected Ugandan adults in WHO
stages 1–3, using invasive pneumococcal disease as the pri-
mary endpoint.64 Approximately 44% of the population had
CD4 cell counts  200  106/L at study entry. There was
no difference in mortality between the vaccine and placebo
groups: 185 versus 182 deaths, unadjusted hazard ratio 
0.99 (95% CI  0.80–1.21). There was a nonsignificant ex-
cess of first episodes of invasive pneumococcal disease in
the vaccine group: 15 versus 10 events, hazard ratio  1.47
(95% CI  0.7–3.3), and a significant excess of all-cause
pneumonia in the vaccine group: 40 versus 21 events, hazard
ratio  1.89 (95% CI  1.1–3.2). This suggests that PPV
has no protective effect in this population and may have
resulted in an increase in episodes of pneumonia.
There are a number of possible explanations for the lack
of efficacy of this intervention. First, the pneumococcal se-
rogroups causing disease in the study population might have
been different from the serotypes included in the 23-valent
vaccine used in the trial. However, this is unlikely since 85%
of invasive isolates of pneumococci in study participants
were with serogroups included in the vaccine. Second, the
vaccine may have failed to induce protective immunity in
the study participants, as has been found previously in HIV-
infected individuals.65 Almost half of the study population
had severe immunosuppression; although there were too few
events to detect a difference in efficacy by CD4 count, the
lack of efficacy is consistent with work showing impaired
immune responses to PPV in HIV-infected individuals with
low CD4 counts.66 However, these studies are difficult to
interpret because antibody responses may not correlate with
clinical protection. Third, the researchers suggest that the
vaccine may have caused destruction of polysaccharide-re-
sponsive B cell clones.
We can conclude that PPV is not beneficial in HIV-in-
fected individuals in this African population, where most
participants were already immunosuppressed. Since most
HIV-infected people in low-income countries make first con-
tact with health services when they already have advanced
immunosuppression, this intervention is unlikely to be useful
in this setting.
What we don’t know. New vaccines to prevent pneu-
mococcal disease are becoming available which may be
more effective in HIV-infected and other ‘‘high-risk’’ pop-
ulations. Polysaccharide antigens induce antibodies indepen-
dent of T cell function, and the immune response is therefore
restricted. They do not induce immunologic memory or mat-
uration of the immune response, and the response is unre-
liable in children younger than two years old, the elderly, or
immunocompromised individuals. To enhance immunoge-
nicity, conjugate vaccines have been developed in which the
polysaccharide antigen is linked to a protein carrier.
Conjugate vaccines against Haemophilus influenzae type
b (Hib) have been highly successful in reducing the inci-
dence of invasive Hib infections in infants. Pneumococcal
conjugate vaccines have been shown to be immunogenic
among children, including those with HIV infection67 and
efficacy studies in children are in progress in South Africa
and The Gambia. Conjugate vaccines may also hold promise
for HIV-infected adults and need to be evaluated. If effec-
tive, the major obstacle to be overcome would be their price,
which is currently prohibitively expensive for use in low-
income countries.
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Conclusions. On the basis of current evidence, PPV can-
not be recommended for HIV-infected people in African
countries. Conjugate vaccines, or strategies combining both
types of vaccine, need to be evaluated.
PREVENTING FUNGAL DISEASE
Cryptococcal disease seems to be an important cause of
HIV-related morbidity and mortality in African countries; it
may be more significant in eastern and southern Africa.
Esophageal candidiasis is also reported as a major cause of
morbidity. Fungal disease can be prevented; in a randomized
controlled trial in the United States, primary preventive ther-
apy with fluconazole was shown to reduce the incidence of
cryptococcal disease, esophageal candidiasis, and superficial
fungal infections among HIV-infected individuals, particu-
larly those with CD4 counts less than 50  106/L.68 Flucon-
azole had no significant effect on mortality in this study,
perhaps because of lack of statistical power to detect a dif-
ference; mortality rates attributable to fungal disease were
low, and the study was not designed to address this issue.
In spite of its efficacy, primary preventive therapy with
fluconazole is not generally recommended as standard of
care in the United States because of the low incidence of
disease, the lack of survival benefit, the risk of promoting
resistance to antifungal drugs, and the toxicity and cost of
imidazole therapy.60 The burden of cryptococcal disease may
be more significant in some regions of Africa. However, in
many countries the current cost of imidazoles is so high that
even symptomatic cryptococcal disease is not treated. In this
situation, preventive therapy with imidazoles is unlikely to
be affordable or cost-effective. However, if generic imidaz-
oles become available, the price may fall substantially69 and
antifungal preventive therapy could be worth further consid-
eration in countries where cryptococcal disease is a major
cause of morbidity and mortality.
CONCLUSIONS
Using drugs that are widely available and relatively in-
expensive, preventive therapy can reduce the incidence of
some of the most important HIV-related diseases relevant to
people in African countries. Optimum regimens will vary
geographically, and regional guidelines for preventive ther-
apy need to be established. Opportunities need to be sought
to implement these regimens within existing health services,
particularly those where HIV counseling and testing is cur-
rently offered. Other opportunities could be created, for ex-
ample, within occupational health settings and among stu-
dents and the military. The effectiveness of these preventive
interventions under operational conditions will need to be
determined. Other priorities in the management of HIV-re-
lated disease include providing essential drugs and improv-
ing palliative care.
The best way to prevent HIV-related disease in sub-Sa-
haran African countries is to prevent new HIV infections,
and to provide effective antiretroviral therapy, although the
implementation of the latter poses a huge challenge. Preven-
tive therapies represent an opportunity to reduce morbidity
and prolong healthy life that could now be offered to many
HIV-infected people in low-income countries, and could, if
widely implemented, have significant impact on morbidity
at the population level. Furthermore, the availability of ef-
fective and affordable regimens to prevent HIV-related dis-
ease may encourage people to seek HIV testing and may
help overcome the sense of powerlessness in countries where
the HIV epidemic has hit hardest.
Addendum:
Since the submission of this article, the trial of cotrimox-
azole versus placebo among HIV-infected adults in Senegal
has been published: there was no difference in morbidity and
mortality between the two groups.71 Recruitment to the study
was terminated early when the results of the study by An-
glaret and others45 were released, and so the number of par-
ticipants was lower than planned, resulting in low study
power. In addition, an observational study from South Africa
has been published in which morbidity and survival were
compared between patients receiving cotrimoxazole and
those not given cotrimoxazole.72 Among individuals in WHO
stages 3 and 4, morbidity was reduced and survival in-
creased among those receiving cotrimoxazole. However,
among individuals in WHO stage 2 or with a CD4 count of
200–500 106/L there was no significant difference in mor-
bidity or survival among those receiving cotrimoxazole. This
was an observational cohort study, not a randomized con-
trolled trial, and therefore there may have been differences
between the two groups which were not controlled for. How-
ever, the results suggest that the maximum benefit from co-
trimoxazole is among individuals with advanced HIV dis-
ease.
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APPENDIX 1
World Health Organization staging system for human immunodeficiency virus infection and disease (provisional)70
Stage 1. Asymptomatic disease or persistent generalized lymphadenopathy.
Stage 2. 10% weight loss; minor mucocutanous manifestations; Herpes zoster within the last 5 years; recurrent upper respiratory tract
infections; and/or performance scale 2: symptomatic, normal activity.
Stage 3. Weight loss 10%; unexplained chronic fever or diarrhea 1 month; oral candidiasis; oral hairy leukoplakia; pulmonary tuberculosis
within the past year; severe bacterial infections; and/or performance scale 3: bed-ridden 50% of the day during the last month.
Stage 4. Human immunodeficiency virus (HIV) wasting syndrome; Pneumocystis carinii pneumonia; cerebral toxoplasmosis; cryptosporidiosis
with diarrhea 1 month; cryptococcosis, extrapulmonary; cytomegalovirus disease of an organ other than liver, spleen or lymph nodes; Herpes
simplex virus infection, mucocutaneous 1 month or visceral any duration; progressive multifocal leukoencephalopathy; disseminated endemic
mycosis; candidiasis of esophagus, trachea, bronchi, or lungs; atypical mycobacteriosis, disseminated; nontyphoid Salmonella septicemia;
extrapulmonary tuberculosis; lymphoma; Kaposi’s sarcoma; HIV encephalopathy; and/or performance scale 4: bed-ridden 50% of the day
during the last month.
